Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1984 Feb;43(2):463-6.
doi: 10.1128/iai.43.2.463-466.1984.

Immunoglobulin classes of Aleutian disease virus antibody

D D Porter, H G Porter, S C Suffin, A E Larsen

Immunoglobulin classes of Aleutian disease virus antibody

D D Porter et al. Infect Immun. 1984 Feb.

Abstract

Aleutian disease virus (ADV) persistently infects mink and causes marked hypergammaglobulinemia. Immunoglobulin class-specific antisera were used to define the total immunoglobulin of each class by radial immunodiffusion and the immunoglobulin class of ADV-specific antibody by immunofluorescence in experimentally and naturally infected mink. Electrophoretic gamma globulin closely reflects the immunoglobulin G (IgG) level in mink, and the majority of the increased immunoglobulin and ADV antibody in infected mink is IgG. IgM becomes elevated within 6 days after infection, reaches peak levels by 15 to 18 days, and returns to normal by 60 days after infection. The first ADV antibody demonstrable is IgM, and most mink have virus-specific IgM antibody for at least 85 days postinfection. Serum IgA levels in normal mink are not normally distributed, and ADV infection causes a marked elevation of IgA. Low levels of ADV-specific IgA antibody can be shown throughout the course of infection. Failure of large amounts of virus-specific IgG antibody to inhibit the reaction of virus-specific IgM and IgA antibodies suggests that the various classes of antibodies are directed against spatially different antigenic determinants. The IgM and IgA were shown not to be rheumatoid factors.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. J Exp Med. 1966 Feb 1;123(2):347-64 - PubMed
    1. J Exp Med. 1965 Jun 1;121:889-900 - PubMed
    1. Lab Invest. 1967 Aug;17(2):123-39 - PubMed
    1. Immunochemistry. 1969 Jan;6(1):53-66 - PubMed
    1. Clin Exp Immunol. 1969 Jan;4(1):101-12 - PubMed

Publication types

LinkOut - more resources